Hamel Lawrence G 4
4 · ACELRX PHARMACEUTICALS INC · Filed Oct 16, 2018
Insider Transaction Report
Form 4
Hamel Lawrence G
Chief Development Officer
Transactions
- Sale
Common Stock
2018-10-15$5.00/sh−5,216$26,080→ 29,795 total(indirect: By Trust)
Holdings
- 24,371
Common Stock
Footnotes (1)
- [F1]Shares sold pursuant to a 10b5-1 plan.